PMID- 38195916
OWN - NLM
STAT- Publisher
LR  - 20240110
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
DP  - 2024 Jan 9
TI  - A multi-center international study to evaluate the safety, functional and 
      oncological outcomes of irreversible electroporation for the ablation of prostate 
      cancer.
LID - 10.1038/s41391-023-00783-y [doi]
AB  - BACKGROUND: Irreversible electroporation (IRE) is a novel technique to treat 
      localized prostate cancer with the aim of achieving oncological control while 
      reducing related side effects. We present the outcomes of localized prostate 
      cancer treated with IRE from a multi-center prospective registry. METHODS: Men 
      with histologically confirmed prostate cancer were recruited to receive IRE. All 
      the patients were proposed for prostate biopsy at 1-year post-IRE ablation. The 
      functional outcomes were measured by the International Prostate Symptom Score 
      (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The 
      safety of IRE was graded by the treatment-related adverse events (AEs) according 
      to the Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: 411 
      patients were recruited in this study from July 2015 to April 2020. The median 
      follow-up time was 24 months (IQR 15-36). 116 patients underwent repeat prostate 
      biopsy during 12-18 months after IRE. Clinically significant prostate cancer 
      (Gleason >/= 3 + 4) was detected in 24.1% (28/116) of the patients; any grade 
      prostate cancers were found in 59.5% (69/116) of the patients. The IPSS score 
      increased significantly from 7.1 to 8.2 (p = 0.015) at 3 months but decreased to 
      6.1 at 6 months (p = 0.017). Afterwards, the IPSS level remained stable during 
      follow-up. The IIEF-5 score decreased at 3 months from 16.0 to 12.1 (p < 0.001) 
      and then maintained equable afterwards. The rate of AEs was 1.8% at 3 months and 
      then dropped to less than 1% at 6 months and remained stable until 48 months 
      after IRE. Major AEs (Grade 3 or above) were rare. CONCLUSION: For men with 
      localized prostate cancer, IRE could achieve good urinary and sexual function 
      outcomes and a reasonable oncological result. The real-world data are consistent 
      with earlier studies, including recently published randomized controlled studies. 
      The long-term oncological results need further investigation and follow-up.
CI  - (c) 2024. The Author(s).
FAU - Zhang, Kai
AU  - Zhang K
AUID- ORCID: 0000-0002-5289-3619
AD  - Department of Urology, Beijing United Family Hospital and Clinics, Beijing, 
      China.
FAU - Stricker, Phillip
AU  - Stricker P
AUID- ORCID: 0000-0002-0934-0656
AD  - Department of Urology, St Vincents Private Hospital Sydney, St Vincents Prostate 
      Cancer Research Centre and The Garvan Institute, Sydney, Australia.
FAU - Lohr, Martin
AU  - Lohr M
AD  - Department of Urology, Klinik fur Prostata-Therapie, Heidelberg, Germany.
FAU - Stehling, Michael
AU  - Stehling M
AD  - VITUS Privatklinik and Institut fur Bildgebende Diagnostik, 
      Strahlenbergerstrasse, Offenbach, Germany.
FAU - Suberville, Michel
AU  - Suberville M
AD  - Doctor Michel SUBERVILLE Chief of Pole, Pole SAINT GERMAIN - CENTRE HOSPITALIER, 
      Brive la Gaillarde, France.
FAU - Cussenot, Olivier
AU  - Cussenot O
AD  - Department of Urology, Tenon Hospital, Paris, France.
FAU - Lunelli, Luca
AU  - Lunelli L
AUID- ORCID: 0000-0002-1162-8923
AD  - Department of Urology, Hospital Louis Pasteur, Chartres, France.
FAU - Ng, Chi-Fai
AU  - Ng CF
AUID- ORCID: 0000-0002-1723-9646
AD  - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong 
      Kong, Hong Kong, China.
FAU - Teoh, Jeremy
AU  - Teoh J
AUID- ORCID: 0000-0002-9361-2342
AD  - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong 
      Kong, Hong Kong, China.
FAU - Laguna, Pilar
AU  - Laguna P
AD  - Department of Urology, Medipol Mega hospital, Istanbul Medipol University, 
      Istanbul, Turkiye.
FAU - de la Rosette, Jean
AU  - de la Rosette J
AUID- ORCID: 0000-0002-6308-1763
AD  - Department of Urology, Medipol Mega hospital, Istanbul Medipol University, 
      Istanbul, Turkiye. j.j.delarosette@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20240109
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
SB  - IM
EDAT- 2024/01/10 06:41
MHDA- 2024/01/10 06:41
CRDT- 2024/01/10 00:05
PHST- 2023/08/09 00:00 [received]
PHST- 2023/12/19 00:00 [accepted]
PHST- 2023/11/08 00:00 [revised]
PHST- 2024/01/10 06:41 [medline]
PHST- 2024/01/10 06:41 [pubmed]
PHST- 2024/01/10 00:05 [entrez]
AID - 10.1038/s41391-023-00783-y [pii]
AID - 10.1038/s41391-023-00783-y [doi]
PST - aheadofprint
SO  - Prostate Cancer Prostatic Dis. 2024 Jan 9. doi: 10.1038/s41391-023-00783-y.